Bradley Mark J. Has $6.54 Million Stake in Eli Lilly and Company (NYSE:LLY)

Bradley Mark J. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.2% during the first quarter, HoldingsChannel reports. The firm owned 19,040 shares of the company’s stock after purchasing an additional 1,435 shares during the quarter. Eli Lilly and Company accounts for approximately 4.7% of Bradley Mark J.’s holdings, making the stock its 2nd biggest position. Bradley Mark J.’s holdings in Eli Lilly and Company were worth $6,539,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Oxler Private Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 0.4% during the 1st quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock valued at $2,078,000 after buying an additional 24 shares in the last quarter. Missouri Trust & Investment Co boosted its stake in Eli Lilly and Company by 3.2% in the 1st quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock worth $266,000 after purchasing an additional 24 shares in the last quarter. Silvercrest Asset Management Group LLC raised its holdings in Eli Lilly and Company by 0.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 4,331 shares of the company’s stock worth $1,487,000 after buying an additional 25 shares during the last quarter. Cora Capital Advisors LLC grew its holdings in shares of Eli Lilly and Company by 2.8% during the first quarter. Cora Capital Advisors LLC now owns 956 shares of the company’s stock valued at $328,000 after buying an additional 26 shares during the last quarter. Finally, Sittner & Nelson LLC increased its position in shares of Eli Lilly and Company by 2.7% during the first quarter. Sittner & Nelson LLC now owns 1,003 shares of the company’s stock valued at $344,000 after acquiring an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $598.88 on Thursday. The firm’s fifty day moving average is $504.85 and its two-hundred day moving average is $433.48. Eli Lilly and Company has a 52-week low of $296.32 and a 52-week high of $601.13. The company has a market cap of $568.51 billion, a P/E ratio of 83.29, a P/E/G ratio of 2.36 and a beta of 0.32. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.25 earnings per share. As a group, analysts anticipate that Eli Lilly and Company will post 9.83 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were given a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a dividend yield of 0.75%. Eli Lilly and Company’s payout ratio is presently 62.87%.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 107,022 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total value of $49,153,064.16. Following the completion of the transaction, the insider now owns 101,248,810 shares of the company’s stock, valued at $46,501,553,456.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $546.51, for a total value of $327,906.00. Following the transaction, the chief accounting officer now owns 5,378 shares of the company’s stock, valued at approximately $2,939,130.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 107,022 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the transaction, the insider now owns 101,248,810 shares of the company’s stock, valued at approximately $46,501,553,456.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,010,309 shares of company stock worth $21,095,701,670. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Morgan Stanley boosted their target price on Eli Lilly and Company from $617.00 to $640.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 5th. Argus raised their target price on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $510.00 to $600.00 and gave the stock an “overweight” rating in a report on Wednesday, August 9th. Finally, BMO Capital Markets increased their target price on Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $532.78.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.